The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 10, 2005, Pages 1269-1274

  Alexander, C ^a   Tarzi, M ^a   Larche M ^a   Kay, A B ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; Epitope; Immunological tlerance; Rhinitis; T lymphocyte

Indexed keywords

ALLERGEN; EPITOPE; FEL D 1 ANTIGEN; IMMUNOGLOBULIN E; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ARTICLE; ASTHMA; CAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DANDER; DISEASE MARKER; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SLEEP; SNEEZING; T LYMPHOCYTE;

ADULT; ANIMALS; ASTHMA; CATS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; MALE; MIDDLE AGED; PEPTIDES; RHINITIS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 24744438448     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00885.x     Document Type: Article

References (12)

1. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001;167:1734-1739.
2. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002;360:47-53.
3. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-754.
4. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999;104:364-369.
5. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999;115:1265-1270.
6. Khan LN, Kon OM, Macfarlane AJ, Meng Q, Ying S, Barnes NC et al. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, IL-5, GM-CSF and eotaxin. Am J Respir Crit Care Med 2000;162:1377-1382.
7. Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus CF et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T-cells of patients allergic to cats. J Allergy Clin Immunol 1998;102: 571-578.
8. Apostolou I, Von Boehmer H. In vivo instruction of suppressor commitment in naive T-cells. J Exp Med 2004;199:1401-1408.
9. Alexander C, Oldfield WL, Shirley K, Larche M, Kay AB. A dosing protocol of allergen-derived T cell peptide epitopes for the treatment of allergic disease. J Allergy Clin Immunol 2001;107:716 abs.
10. Smith TRF, Alexander C, Kay AB, Larché M, Robinson DS. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: double-blind placebo-controlled study. Allergy 2004;59:1097-1101.
11. Verhoef A, Alexander C, Kay AB, Larche M. Allergen-based peptide immunotherapy is associated with functional modifications in allergen-specific T cell subpopulations. J Allergy Clin Immunol 2004;113:S255.
12. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999;189:1885-1894.